The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that AstraZeneca AB's Evusheld, developed for the prevention of COVID-19 in adults and adolescents aged 12 years and over and weighing at least 40kg before possible exposure to the SARS-CoV-2 virus that causes the disease, be granted marketing authorisation. [ACCORDING TO A STATEMENT, EVUSHELD CONSISTS OF THE ACTIVE SUBSTANCES TIXAGEVIMAB AND CILGAVIMAB, TWO MONOCLONAL ANTIBODIES DESIGNED TO BIND TO THE SPIKE PROTEIN OF THE SARS-COV-2 VIRUS (THE VIRUS THAT CAUSES COVID-19 DISEASE) AT TWO DIFFERENT SITES. WHEN THE EVUSHELD ANTIBODIES BIND TO THE SPIKE PROTEIN, THE VIRUS CANNOT ENTER THE CELLS TO REPLICATE AND CANNOT CAUSE COVID-19 DISEASE.
(CNA)
CNA George Kakouris
Contents of this article including associated images are owned by CNA
Views & opinions expressed are those of the author and/or CNA
Source
